Potent dual MAGL/FAAH inhibitor AKU-005 engages endocannabinoids to diminish meningeal nociception implicated in migraine pain

Overview of attention for article published in The Journal of Headache and Pain, April 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (75th percentile)
Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

twitter: 10 X users

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 11 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 11 X posts from 10 X users, with an upper bound of 37,516 followers.

RT @StellaLab11: CB-JC.3: eCBs & migraine. A dual MAGL/FAAH inhibitor increases AEA and 2-AG levels in rats and human meninge samples, and…

13 May 2023

Reply Repost Favourite

RT @StellaLab11: CB-JC.3: eCBs & migraine. A dual MAGL/FAAH inhibitor increases AEA and 2-AG levels in rats and human meninge samples, and…

13 May 2023

Reply Repost Favourite

CB-JC.3: eCBs & migraine. A dual MAGL/FAAH inhibitor increases AEA and 2-AG levels in rats and human meninge samples, and decreases excitation of nerve fibres induced by KCl, potential involvement of CB1R. Interesting approach for a devastating conditi

12 May 2023

Reply Repost Favourite

RT @NeuroPsychBMC: Read the #JHeadachedPain featured article from April: Potent dual MAGL/FAAH inhibitor AKU-005 engages endocannabinoids t…

03 May 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 7 additional X posts.